Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.49 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 10/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2640435 | 0.84 | AHR (0.53) | JAK2ALDH1A3JAK3PTK2NUDT1 | |
| SCHEMBL2640342 | 0.84 | JAK2 (0.71) | JAK2JAK3PTK2NUDT1JAK1 | |
| SCHEMBL2640385 | 0.82 | JAK2 (0.55) | JAK2ALDH1A3JAK3PTK2PSEN1 | |
| SCHEMBL2254333 | 0.81 | JAK2 (0.49) | JAK2ALDH1A3JAK3PTK2PSEN1 | |
| SCHEMBL2254342 | 0.81 | JAK2 (0.72) | JAK2ALDH1A3JAK3PTK2NUDT1 | |
| SCHEMBL2640622 | 0.81 | JAK2 (0.50) | JAK2JAK3PTK2NUDT1PSEN1 | |
| SCHEMBL2640453 | 0.79 | JAK2 (0.72) | JAK2JAK3PTK2JAK1 | |
| SCHEMBL2640556 | 0.79 | JAK2 (0.50) | JAK2JAK3PTK2NUDT1JAK1 | |
| SCHEMBL27038151 | 0.76 | PDE10A (0.40) | JAK2JAK3PTK2NUDT1 | |
| SCHEMBL2640671 | 0.76 | JAK2 (0.54) | JAK2JAK3PTK2NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633173-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8501936-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2438066-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES | Cephalon, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010141796-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES | CEPHALON, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | JAK2, JAK1, JAK3 | JAK2 1/4885ALDH1A3 4046/4885JAK3 3/4885 |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CCNA1, CCNY, RB1 | JAK2 31/4885ALDH1A3 2102/4885JAK3 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.